This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech Mailbag

BOSTON -- Thanks for returning to the Biotech Mailbag. Let's get right to your emails. This week:

  • Xoma (XOMA - Get Report),

  • Vanda Pharmaceuticals (VNDA - Get Report),

  • Onyx Pharmaceuticals (ONXX), and

  • Arena Pharmaceuticals (ARNA - Get Report).

    The first email is from David R., who writes, "Has Xoma ever earned a cent? I don't think so. It's amazing that such a nothing company can survive so long."

    Yes, Xoma has earned a cent. In fact, the company posted a profit of $21.8 million, or 16 a share, in the third quarter.

    But I think I know where David is going with his question. Yes, Xoma eked out a profit last quarter, but the company is expected to lose money for the full year, and its accumulated deficit was $730 million as of the end of the third quarter.

    So, Xoma shouldn't really be thought of as a profitable biotech company just yet. But then, red ink flows like water in Biotechland, so Xoma is no different from most. I wouldn't necessarily harp on the company for this.

    I pretty much laid out the Xoma investment story in a column at the end of November, and not much has changed. The speculation that Xoma would put itself up for sale has died down. From what I hear, management seems unable or unwilling to sell the company at this point. This despite the fact that new CEO Steven Engle's employment contract appears to give him an incentive to find a buyer now that 2007 is behind us. If you want more detail, read the company's 8-K filed last Aug. 7.

    Xoma filed a $150 million shelf at the end of December, so that, plus dimming odds on a near-term takeout, has weighed on the stock, which is back under $3.

    The next best bet for a Xoma move is data from XOMA 052, one of the company's lead pipeline drugs, expected in the spring. XOMA 052 is a monoclonal antibody that targets IL-1 beta, which is believed to play a role in diabetes and inflammatory/autoimmune diseases like rheumatoid arthritis.

    Xoma is conducting two phase I studies of XOMA 052 in Type 2 diabetes patients. Obviously, there is limited information that will come from early stage studies like these, but if Xoma can show positive proof of concept with the drug, the hope is that investors (and potential partners) get excited.

    Of course, don't forget about that shelf. If the stock moves higher, don't be surprised to see Xoma raise money.

    Kris B. emails to ask about Vanda:

    "I would like to know your analysis of Vanda Pharmaceuticals. I am a realist and think iloperidone gets an approvable letter later this year and forces Vanda to run another trial examining the QTc issue. However, I am long at this current price, $5.75, and left wondering why there is very little value placed on two successful phase III drugs and over $3.50 a share in cash."

    Vanda is pitching iloperidone as safer and better tolerated than currently used schizophrenia drugs like Risperdal or Geodon. But that's not borne out, necessarily, in the phase III data presented last month.

    Iloperidone looks like a me-too drug on efficacy, with a mixed-to-worse side effect profile compared with currently marketed schizophrenia drugs. It may cause fewer movement disorders (a plus), but more weight gain and a worse metabolic profile, which puts patients at risk for diabetes (not good). I don't think the QTc (irregular heartbeat) issue is resolved, either.

    Kris succinctly articulates the bull argument on Vanda right now, which is that the stock is cheap and expectations are low, so owning Vanda seems like a low-risk bet. It closed the week at $5.27.
    1 of 2

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Real Money

    More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

    Product Features:
    • Access to Jim Cramer's daily blog
    • Intraday commentary and news
    • Real-time trading forums
    Only $49.95
    14-Days Free
    14-Days Free
    ONXX $0.00 0.00%
    ARNA $1.52 0.00%
    VNDA $7.94 0.00%
    XOMA $0.77 0.00%
    AAPL $93.99 0.00%


    Chart of I:DJI
    DOW 15,973.84 +313.66 2.00%
    S&P 500 1,864.78 +35.70 1.95%
    NASDAQ 4,337.5120 +70.6750 1.66%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs